ANGION BIOMEDICA
#3695 COMPANY RANKING
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York.
Since 1998
Claim This Company
Angion Biomedica's stories on HackerNoon
Technology evolves every day, impacting our lives more and more. Don’t miss out on the tech of tomorrow via these remarkable technology stories.
Meet the Winners of Startups in North and Central America
Mon Feb 28 2022 By Startups of The Year
Angion Biomedica's latest news & mentions
Explore a rich selection of stories about your favorite games, how they are made, and the people that make them, from gamers and game developers worldwide.Ischemia Reperfusion Injury Treatment Market: Paving the Way to a $1.58 Billion Valuation by 2033 through Harmonious Healing-FMI Projection
fmiblog.com
Wed Nov 01 2023
Oxford BioMedica PLC (OXB)
investing.com
Wed Oct 18 2023
Chutes & Ladders—CEPI's founding CEO set to lead public health charity Wellcome
fiercebiotech.com
Fri Oct 13 2023
Director dealings: TUI, Oxford Biomedica board members linked to buys
sharecast.com
Fri Oct 13 2023
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
markets.businessinsider.com
Wed Oct 11 2023
Is Angion Biomedica Corp (ELTX) Stock a Good Investment?
aaii.com
Fri Oct 06 2023
Ischemia Reperfusion Injury Therapeutics Market Market Share |Scope|Forecast
linkedin.com
Tue Oct 03 2023
Liver Diseases Treatment Market | Abbott Laboratories, Achillion Pharmaceuticals, Angion Biomedica, BPL Medical Technologies
benzinga.com
Mon Oct 02 2023
Mechanisms of Disease: Mechanisms of Hepatic Fibrosis and Therapeutic Implications
medscape.com
Mon Oct 02 2023
Leading Companies like Roche and Novartis at the Helm of the Global Rapidly Expanding IPF Treatment Market to 2030
finance.yahoo.com
Tue Sep 26 2023
Ischemia Reperfusion Injury Treatment Market: Harmonizing Healing on a Path to US$ 1580 Million by 2033
pharmiweb.com
Tue Sep 26 2023
Analysts Just Slashed Their Oxford Biomedica plc (LON:OXB) EPS Numbers
finance.yahoo.com
Mon Sep 25 2023
Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Projected to Reach $6.17 Billion by 2030: Increasing Prevalence Drives Growth
finance.yahoo.com
Fri Sep 22 2023
Oxford Biomedica lines up ABL Europe deal
insidermedia.com
Thu Sep 21 2023
Oxford BioMedica shares boom as manufacturer expands complex cancer therapies
thenationalnews.com
Thu Sep 21 2023
Oxford Biomedica lines up ABL Europe deal
insidermedia.com
Thu Sep 21 2023
Oxford Biomedica is optimistic against the odds
investorschronicle.co.uk
Thu Sep 21 2023
Oxford Biomedica lines up ABL Europe deal
insidermedia.com
Thu Sep 21 2023
Acute Kidney Injury Treatment Market | Angion Biomedica Corp, Asahi Kasei Medical Co., Ltd, B. Braun Melsungen AG
benzinga.com
Thu Sep 21 2023
CDMOs SK pharmteco, Oxford Biomedica make cell and gene therapy manufacturing M&A plays
fiercepharma.com
Thu Sep 21 2023
Oxford BioMedica shares soar as vaccine maker raises earnings guidance
ft.com
Thu Sep 21 2023
Oxford Biomedica lines up ABL Europe deal
insidermedia.com
Thu Sep 21 2023
Oxford Biomedica lines up ABL Europe deal
insidermedia.com
Thu Sep 21 2023
Oxford Biomedica lines up ABL Europe deal
insidermedia.com
Thu Sep 21 2023
